This Evolving Paradigm Roundtable reviews the later-line options for patients with hormone receptor–positive, HER2-low or -negative inoperable or metastatic breast cancer, as discussed by key opinion leaders and participants at virtual live events.
Incorporating Datopotamab Deruxtecan in Advanced Breast Cancer
April 9th 2024During a Case-Based Roundtable® event, Virginia G. Kaklamani, MD, discussed the use of datopotamab deruxtecan in patients with advanced breast cancer and how next-generation sequencing plays an important role in their treatment in the second article of a 2-part series.